Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Rezurock belumosudil Graft-versus-host disease Reimburse with clinical criteria and/or conditions Active
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete
Akeega niraparib abiraterone acetate Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Active
Brukinsa zanubrutinib Chronic lymphocytic leukemia /small lymphocytic lymphoma. Reimburse with clinical criteria and/or conditions Complete
Welireg belzutifan von Hippel-Lindau disease-associated tumours Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Zoryve roflumilast Plaque psoriasis Reimburse with clinical criteria and/or conditions Complete
Xcopri cenobamate Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Imcivree setmelanotide Bardet-Biedl syndrome Reimburse with clinical criteria and/or conditions Complete
Cabometyx cabozantinib Advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete